So I'll give you my view and then maybe Steve will add to it as well. So it's a bit of a misnomer when you talk about overcapacity in '23 or '24, when you look at where is the CapEx being spent by the industry, industry spent over $100 million of CapEx last year. The vast majority of that CapEx, over 90% of it, is being spent on the bleeding edge nodes. These are the nodes that are 16-nanometer and smaller, so 16, 10, 7, 5, 3, et cetera, is where all that is being spent. Where the capacity is not being invested in at the rates that are required, and where, for example, all of the constraints that the industry is fighting through short, medium and long term, are on these trailing edge, specialty technologies. On 300-millimeter, that is typically anything which is 40-nanometer and larger in size, very little capacity investment coming online to be able to help that. On 200-millimeter, 8-inch wafers, there's almost nothing that is being done, outside of what some of the IDMs have been doing and which really is still a far cry from what is needed. So while there is CapEx spending taking place of quite significant amount, it is being spent disproportionately on the bleeding edge technologies, and there are still significant constraints left on the trailing edge, specialty technologies that we don't see easing up into '23 and '24. Steve, do you want to add some more to it?